07/22/2026
We're proud to announce that NHO Revive expects to activate an Expanded Access Protocol (EAP) for Daraxonrasib as early as next week.
This program may provide eligible patients with stage 4 pancreatic cancer access to this investigational therapy before potential FDA approval, offering an additional treatment option for patients whose current therapy is no longer effective or cannot be tolerated.
Once the protocol is active, we'll begin accepting referrals from healthcare providers and inquiries from patients interested in learning whether they may qualify.
Read the full announcement to learn more about the Expanded Access Protocol and eligibility requirements.
https://www.yourcancercare.com/nho-announces-expanded-access-protocol-pancreatic-cancer-trial